GlobeNewsWire
03 Aug 2026, 10:35 UTC · 6w ago
Verdict
Headline takes no side. We score SUPN +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Supernus Pharmaceuticals has entered into an agreement to merge with Indivior Pharmaceuticals in a merger of equals.
So whatMergers typically trigger significant price action due to changes in scale, synergy potential, and fundamental company valuation.
More positive than 92% of claims this week
Supernus is raising its full year 2026 financial guidance.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of claims this week
The company reported continued strength and sustained momentum in its growth products for the first half of 2026.
So whatPositive operational updates confirm stability in the core business, though less impactful than a merger or guidance raise.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company reported strength in growth products, raised its full-year 2026 financial guidance, and announced a strategic merger.
More positive than 70% of ticker scores this week
The company entered into a merger of equals with Supernus to create a well-positioned CNS company with increased scale.
More positive than 40% of ticker scores this week
Mentioned as a collaborator providing revenue streams via ZURZUVAE sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
More positive than 97% of relationship scores this week
[a_to_b] The text references the closing of Biogen's acquisition of Sage Therapeutics.
More positive than 37% of relationship scores this week
[mutual] Supernus maintains a collaboration agreement with Biogen for the sale of ZURZUVAE.
−5.9%
Price is moving against the score
$42.00 vs $44.63 close before publication (Jul 31) · not market-adjusted
SUPN chart →
